Heart failure is a complex syndrome which results from the heart’s inability to pump enough blood to meet the body’s needs. Clinical presentation typically is with shortness of breath, fatigue and signs of fluid retention. The most common cause is myocardial infarction.
Heart failure affects 1 – 2% of the UK population; the incidence and prevalence increase significantly with age, affecting approximately 7% of those aged 75 – 85 years. Overall prognosis and patient quality of life are poor; 14% of newly diagnosed patients die within the first six months, the average life expectancy is approximately 3 years and physical and social limitations for the patient are significant. The expenditure for heart failure is approximately 1 – 2% of the NHS budget, mainly related to costs of hospital based patient management. Our research focuses on outcome measures which assess patient satisfaction and the delivery of specialist care to support heart failure management within the community.
Key research activities
- Assessment of the Impact of Patient Oriented Outcome Measures
The most powerful strategy for protecting the heart against acute ischaemia-reperfusion injury is to utilize the endogenous mechanisms through which the heart protects itself from extrinsic insults - this phenomenon has been termed ‘conditioning’. Using a translational approach this can be achieved using either mechanical or pharmacological ‘conditioning’ strategies. Studies are undertaken in both the basic science laboratory as well as in the clinical setting of coronary artery bypass surgery and percutaneous coronary intervention.
- Development of an Integrated Community Based Heart Failure Service
Our research aims to develop and evaluate the impact (quality, efficacy) of a community focused heart failure service which is integrated with the hospitals provision of care working within the UCL Partners and NC London network structure.
- Assessment of Percutaneous Device Therapies in Heart Failure
Novel percutaneous treatments for heart failure and associated complications are in development. Our work explores outcomes of a percutaneous device to reduce left ventricular volume and percutaneous Mitraclip technology in patient with heart failure and secondary mitral regurgitation.